CalciMedica (NASDAQ:CALC) Upgraded by Singular Research to Moderate Buy

Singular Research upgraded shares of CalciMedica (NASDAQ:CALC) to a moderate buy rating in a research report released on Friday, Zacks.com reports.

Several other equities analysts also recently weighed in on the stock. HC Wainwright reaffirmed a buy rating and set a $20.00 price target on shares of CalciMedica in a report on Thursday, June 27th. Oppenheimer reaffirmed an outperform rating and set a $14.00 price target on shares of CalciMedica in a report on Monday, April 1st.

CalciMedica Trading Up 7.3 %

CALC opened at $4.25 on Friday. CalciMedica has a 12-month low of $1.75 and a 12-month high of $8.38. The company has a market cap of $45.69 million, a price-to-earnings ratio of -1.98 and a beta of 1.28. The company’s 50 day moving average is $5.26 and its 200 day moving average is $4.63.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.07. As a group, analysts predict that CalciMedica will post -2.05 EPS for the current fiscal year.

Insider Transactions at CalciMedica

In related news, Director Robert N. Wilson bought 8,443 shares of the stock in a transaction dated Thursday, June 27th. The shares were purchased at an average price of $3.23 per share, with a total value of $27,270.89. Following the completion of the acquisition, the director now owns 258,918 shares of the company’s stock, valued at $836,305.14. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 53.30% of the company’s stock.

Institutional Investors Weigh In On CalciMedica

Several large investors have recently bought and sold shares of CALC. Hudson Bay Capital Management LP bought a new stake in CalciMedica in the third quarter worth $432,000. BML Capital Management LLC increased its position in CalciMedica by 63.8% in the fourth quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock worth $416,000 after purchasing an additional 56,643 shares during the last quarter. Finally, Meritage Portfolio Management increased its position in CalciMedica by 360.0% in the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after purchasing an additional 36,000 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.